Pancreatic cancer: Advances and challenges
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer
Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
T Conroy, F Castan, A Lopez, A Turpin… - JAMA …, 2022 - jamanetwork.com
Importance Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
The multicenter cancer of pancreas screening study: impact on stage and survival
PURPOSE To report pancreas surveillance outcomes of high-risk individuals within the
multicenter Cancer of Pancreas Screening-5 (CAPS5) study and to update outcomes of …
multicenter Cancer of Pancreas Screening-5 (CAPS5) study and to update outcomes of …
Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer
MS Lee, C Dennis, I Naqvi, L Dailey, A Lorzadeh, G Ye… - Nature, 2023 - nature.com
There is a need to develop effective therapies for pancreatic ductal adenocarcinoma (PDA),
a highly lethal malignancy with increasing incidence and poor prognosis. Although targeting …
a highly lethal malignancy with increasing incidence and poor prognosis. Although targeting …
Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment
G Werba, D Weissinger, EA Kawaler, E Zhao… - Nature …, 2023 - nature.com
The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) is a
complex ecosystem that drives tumor progression; however, in-depth single cell …
complex ecosystem that drives tumor progression; however, in-depth single cell …
Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer entity characterized by a
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …
Racial and ethnic differences in hysterectomy-corrected uterine corpus cancer mortality by stage and histologic subtype
MA Clarke, SS Devesa, A Hammer… - JAMA oncology, 2022 - jamanetwork.com
Importance Uterine cancer incidence has been increasing, particularly rates of aggressive,
nonendometrioid subtypes, which are disproportionately higher among non-Hispanic Black …
nonendometrioid subtypes, which are disproportionately higher among non-Hispanic Black …
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) has one of the worst prognoses among all
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …
malignancies. PI3K/AKT/mTOR signaling pathway, a main downstream effector of KRAS is …
Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin …
The present study deals with the advanced in-silico analyses of several Apigenin derivatives
to explore human papillomavirus-associated cervical cancer and DNA polymerase theta …
to explore human papillomavirus-associated cervical cancer and DNA polymerase theta …